Y536S News

Mesoblast Gets FDA's Special Pediatric Designation for Revascor Heart Treatment

By Dean Seal Mesoblast said regulators have granted their rare pediatric disease designation to its cell therapy Revascor for children with...

Mesoblast ADSs Plunge Premarket on Latest FDA Rejection

By Colin Kellaher American depositary shares of Mesoblast plummeted more than 65% in premarket trading Friday after the biopharmaceutical...

FDA Schedules Pre-License Inspection of Remestemcel-L Manufacturing

Biologics License Application (BLA) Resubmission for Pediatric Acute Graft-Versus-Host Disease (SR-aGVHD...

Mesoblast ADSs Rally as FDA Accepts Remestemcel-L Resubmission

By Colin Kellaher American depositary shares of Mesoblast Ltd. jumped more than 15% in early trading Wednesday after the biopharmaceutical company...

Mesoblast Shares Rise 11% After Resubmitting Biologics License Application

By Chris Wack Mesoblast Ltd. shares were up 11% to $3.67 Wednesday after the company said it resubmitted a biologics license application to the...

Mesoblast Shares Rise 10% After New Info Submitted to FDA for Remestemcel-L

By Chris Wack Mesoblast Ltd. shares were up 10% to $2.80 after the company said it submitted substantial new information to the U.S. Food and Drug...

Mesoblast to Hold Type C Meeting With FDA for Back Pain Treatment

By Chris Wack Mesoblast Ltd. said it has filed a request and expects to hold a Type C meeting with the U.S. Food & Drug Administration during...

Mesoblast Up 25% After Hours on Collaboration With Novartis

By Josh Beckerman Mesoblast Ltd. American depositary receipts surged 25% to $14.70 after hours as the company entered an exclusive worldwide...

Mesoblast Named Global Technology Leader in Cell Therapy Industry

Mesoblast Limited has been named by Frost & Sullivan as the 2017 Global Technology Leader in the Cell Therapy Industry. Mesoblast is...

Mesoblast’s Japan Licensee Receives Pricing for TEMCELL® HS Inj. for Treatment of Acute Graft Versus Host Disease

MELBOURNE, Australia and NEW YORK, Nov. 27, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that its...

Mesoblast Investor Update

MELBOURNE, Australia and NEW YORK, Nov. 23, 2015 (GLOBE NEWSWIRE) -- The Mesoblast Board and management are committed to delivering the Tier...

Asian Shares Mostly Higher

Australian shares are nearing their highest level since late October on Monday, though falling commodities prices muted gains triggered by...

Australia Shares End Down, Weighed by China Trade Data

By Robb M. Stewart MELBOURNE, Australia--A fresh assault by Australia's equities market on a seven-year high was deflected by weak trade data out...

Celgene Buys Mesoblast Stake

MELBOURNE, Australia--U.S. biopharmaceutical company Celgene Corp. (CELG) agreed to buy a stake in Australian regenerative-medicine specialist...

Celgene Buys Mesoblast Stake

By Robb M. Stewart MELBOURNE, Australia--U.S. biopharmaceutical company Celgene Corp. (CELG) agreed to buy a stake in Australian...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Y536S (Y536S)

Empower your portfolio: Real-time discussions and actionable trading ideas.

Mesoblast Gets FDA's Special Pediatric Designation for Revascor Heart Treatment

Mesoblast ADSs Plunge Premarket on Latest FDA Rejection

FDA Schedules Pre-License Inspection of Remestemcel-L Manufacturing

Mesoblast ADSs Rally as FDA Accepts Remestemcel-L Resubmission

Mesoblast Shares Rise 11% After Resubmitting Biologics License Application

Mesoblast Shares Rise 10% After New Info Submitted to FDA for Remestemcel-L

Mesoblast to Hold Type C Meeting With FDA for Back Pain Treatment

Mesoblast Up 25% After Hours on Collaboration With Novartis

Mesoblast Named Global Technology Leader in Cell Therapy Industry

Mesoblast’s Japan Licensee Receives Pricing for TEMCELL® HS Inj. for Treatment of Acute Graft Versus Host Disease

Mesoblast Investor Update

Asian Shares Mostly Higher

Australia Shares End Down, Weighed by China Trade Data

Celgene Buys Mesoblast Stake

Celgene Buys Mesoblast Stake

Y536S Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Y536S (Y536S) News

Y536S (Y536S)

Empower your portfolio: Real-time discussions and actionable trading ideas.

Y536S News

Mesoblast Gets FDA's Special Pediatric Designation for Revascor Heart Treatment

Mesoblast ADSs Plunge Premarket on Latest FDA Rejection

FDA Schedules Pre-License Inspection of Remestemcel-L Manufacturing

Mesoblast ADSs Rally as FDA Accepts Remestemcel-L Resubmission

Mesoblast Shares Rise 11% After Resubmitting Biologics License Application

Mesoblast Shares Rise 10% After New Info Submitted to FDA for Remestemcel-L

Mesoblast to Hold Type C Meeting With FDA for Back Pain Treatment

Mesoblast Up 25% After Hours on Collaboration With Novartis

Mesoblast Named Global Technology Leader in Cell Therapy Industry

Mesoblast’s Japan Licensee Receives Pricing for TEMCELL® HS Inj. for Treatment of Acute Graft Versus Host Disease

Mesoblast Investor Update

Asian Shares Mostly Higher

Australia Shares End Down, Weighed by China Trade Data

Celgene Buys Mesoblast Stake

Celgene Buys Mesoblast Stake

Y536S Discussion

Your Recent History